CNBC June 21, 2024
Annika Kim Constantino

Key Points

– Eli Lilly said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing disorder and expects regulators to make a decision as early as the end of the year.

– The company released additional data from two late-stage trials showing that Zepbound helped resolve obstructive sleep apnea in almost half of patients.

– The results add to growing evidence of additional health benefits tied to a buzzy class of weight loss and diabetes treatments, which have skyrocketed in popularity in the U.S. over the past year.

Eli Lilly on Friday said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs
Pfizer, Valneva inch closer to FDA approval of 1st Lyme disease vaccine
New Gene Therapy for Muscular Dystrophy May Facilitate Development of Others
Weight Loss Drugs’ Effects Could Be Improved by Priming Melanocortin System
J&J IRA pricing offer is in, as it sticks with 2025 guidance

Share This Article